Trial Profile
Clinical features of metastatic renal cell carcinoma patients with intrinsic resistance to sunitinib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Aug 2015
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 14 Aug 2015 New trial record